Schnitzler Syndrome Latest Advances

Clinical effectiveness and safety of anakinra in an octogenarian patient with Schnitzler Syndrome.

Journal: Italian journal of dermatology and venereology

Published: March 16, 2026

No mistakes with Schnitzler syndrome

Journal: Praxis

Published: January 22, 2026

Letter to the editor - "Re: Tinea labialis in a patient with Schnitzler syndrome on interleukin-1 receptor antagonist".

Journal: JAAD case reports

Published: January 16, 2026

Schnitzler Syndrome as an Autoinflammatory Disease Driven by B-Cell-Specific Somatic MYD88 Mutation.

Journal: Allergy

Published: January 15, 2026

Tinea labialis in a patient with Schnitzler syndrome on interleukin-1 receptor antagonist.

Journal: JAAD case reports

Published: October 13, 2025

Comment on 'Schnitzler syndrome without monoclonal gammopathy: a systematic review and case presentation'.

Journal: Clinical and experimental dermatology

Published: September 17, 2025

A Modern Look at Schnitzler Syndrome - A Literature Review.

Journal: Acta dermatovenerologica Croatica : ADC

Published: July 14, 2025

IgA λ-Type Schnitzler Syndrome With Edema and Numbness.

Journal: The Journal of dermatology

Published: July 13, 2025

Schnitzler syndrome without monoclonal gammopathy: a systematic review and case presentation.

Journal: Clinical and experimental dermatology

Published: June 17, 2025

Canakinumab as effective therapy in anakinra-refractory Schnitzler syndrome: a case-based review.

Journal: Internal medicine journal

Published: March 31, 2025

IL-1 targeting agents in Schnitzler syndrome: a multicentre, real-world study from the international AIDA Network Schnitzler Registry.

Journal: Clinical and experimental rheumatology

Published: February 27, 2025

Neutrophils predominate as IL1B-expressing cells in Schnitzler syndrome: Insights from the SCan study to evaluate the efficacy and safety of canakinumab in Japanese patients.

Journal: Allergology international : official journal of the Japanese Society of Allergology

Published: February 10, 2025

Schnitzler Syndrome Latest Advances

Find the Latest Research About Schnitzler Syndrome

Clinical effectiveness and safety of anakinra in an octogenarian patient with Schnitzler Syndrome.

Clinical effectiveness and safety of anakinra in an octogenarian patient with Schnitzler Syndrome.

No mistakes with Schnitzler syndrome

No mistakes with Schnitzler syndrome

Letter to the editor - "Re: Tinea labialis in a patient with Schnitzler syndrome on interleukin-1 receptor antagonist".

Letter to the editor - "Re: Tinea labialis in a patient with Schnitzler syndrome on interleukin-1 receptor antagonist".

Schnitzler Syndrome as an Autoinflammatory Disease Driven by B-Cell-Specific Somatic MYD88 Mutation.

Schnitzler Syndrome as an Autoinflammatory Disease Driven by B-Cell-Specific Somatic MYD88 Mutation.

Tinea labialis in a patient with Schnitzler syndrome on interleukin-1 receptor antagonist.

Tinea labialis in a patient with Schnitzler syndrome on interleukin-1 receptor antagonist.

Comment on 'Schnitzler syndrome without monoclonal gammopathy: a systematic review and case presentation'.

Comment on 'Schnitzler syndrome without monoclonal gammopathy: a systematic review and case presentation'.

A Modern Look at Schnitzler Syndrome - A Literature Review.

A Modern Look at Schnitzler Syndrome - A Literature Review.

IgA λ-Type Schnitzler Syndrome With Edema and Numbness.

IgA λ-Type Schnitzler Syndrome With Edema and Numbness.

Schnitzler syndrome without monoclonal gammopathy: a systematic review and case presentation.

Schnitzler syndrome without monoclonal gammopathy: a systematic review and case presentation.

Canakinumab as effective therapy in anakinra-refractory Schnitzler syndrome: a case-based review.

Canakinumab as effective therapy in anakinra-refractory Schnitzler syndrome: a case-based review.

IL-1 targeting agents in Schnitzler syndrome: a multicentre, real-world study from the international AIDA Network Schnitzler Registry.

IL-1 targeting agents in Schnitzler syndrome: a multicentre, real-world study from the international AIDA Network Schnitzler Registry.

Neutrophils predominate as IL1B-expressing cells in Schnitzler syndrome: Insights from the SCan study to evaluate the efficacy and safety of canakinumab in Japanese patients.

Neutrophils predominate as IL1B-expressing cells in Schnitzler syndrome: Insights from the SCan study to evaluate the efficacy and safety of canakinumab in Japanese patients.